• 1.

    General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. In: United States Pharmacopeia and National Formulary (USP 43-NF 38). Revised January 1, 2014. Rockville, MD: The United States Pharmacopeia Convention Inc; 2020.

  • 1.

    Proposed Revisions to <795> Pharmaceutical Compounding – Nonsterile Preparations. The United States Pharmacopeia Convention Inc; 2021. Available at: https://go.usp.org/l/323321/2021-08-31/5kmcjf/323321/1630438802OI493yjz/BUD_Scientific_Rationale_for_the_2021_Proposed_Revisions_to__795_.docx. Accessed November 15, 2021.

  • 1.

    Pancorbo SA, Campagna KD, Devenport JK, et al.Task force report of competency statements for pharmacy practice. Am J Pharm Educ. 1987; 51:196–206.

    • Search Google Scholar
    • Export Citation
  • 2.

    Allen LV Jr. Establishing and marketing your extemporaneous compounding service. US Pharm. 1990; 15(Dec):74–7.

  • 3.

    Remington's pharmaceutical sciences. 18th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990; 1630–1, 1658, 1660.

  • 4.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989.

    • Search Google Scholar
    • Export Citation
  • 5.

    USP DI Volume III: Approved drug products and legal requirements. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 6.

    USP DI Volume I: Drug information for the health care professional. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 7.

    29 §C.F.R. 1910. 1200(1990).

  • 8.

    ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

  • 9.

    Feinberg JL. Complying with OSHA's Hazard Communication Standard. Consult Pharm. 1991; 6:444, 446, 448.

  • 10.

    Myers CE. Applicability of OSHA Hazard Communication Standard to drug products. Am J Hosp Pharm. 1990; 47:1960–1.

  • 11.

    21 C.F.R. §211.137.

  • 12.

    Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: Wiley; 1986.

  • 13.

    American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50:305–14.

    • Search Google Scholar
    • Export Citation
  • 14.

    Fitzgerald WL Jr. The legal authority to compound in pharmacy practice. Tenn Pharm. 1990; 26(Mar):21–2.

  • 1.

    Associated Press. Pittsburgh woman loses eye to tainted drugs; 12 hurt. Baltimore Sun. 1990; Nov 9:3A.

  • 2.

    Associated Press. Eye drop injuries prompt an FDA warning. N Y Times. 1990; 140(Dec 9):39I.

  • 3.

    Jeglum EL, Rosenberg SB, Benson WE. Preparation of intravitreal drug doses. Ophthalmic Surg. 1981; 12:355–9.

  • 4.

    Reynolds LA. Guidelines for preparation of sterile ophthalmic products. Am J Hosp Pharm. 1991; 48:2438–9.

  • 5.

    Reynolds LA, Closson R. Ophthalmic drug formulations. A handbook of extemporaneous products. Vancouver, WA: Applied Therapeutics; 1993.

  • 6.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989:1692–3.

  • 7.

    Allen LV. Indomethacin 1% ophthalmic suspension. US Pharm. 1991; 16(May):82–3.

  • 8.

    American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

    • Search Google Scholar
    • Export Citation
  • 9.

    OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm. 1986; 43:1193–204.

  • 10.

    Ansel HC, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 5th ed. Philadelphia: Lea & Febiger; 1990:354–7.

  • 11.

    Stolar MH. Expiration dates of repackaged drug products. Am J Hosp Pharm. 1979; 36:170. Editorial.

  • 12.

    Remington's pharmaceutical sciences. 19th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990:1581–959.

Captopril Solution 1 mg/mL*

in Extemporaneous Formulations
Authors: Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
DOI:
https://doi.org/10.37573/9781585286522.025
Free access

INGREDIENTS:

Captopril 50 mg tablet2 tablets
Sodium ascorbate injection500 mg
Distilled waterQSAD: 100 mL

EQUIPMENT AND SUPPLIES:

Graduated cylinder

PREPARATION DETAILS:

  1. Place tablets in graduated cylinder.

  2. Add distilled water slowly while dissolution occurs.

  3. Add sodium ascorbate injection to graduated cylinder.

  4. Add remaining distilled water to graduated cylinder to achieve the total volume indicated above.

  5. Transfer the solution into an appropriately sized amber bottle.

  6. Shake well to mix.

Alternatives — May substitute additive with ascorbic acid 500 mg tablet, with stability of 56 days when refrigerated or 28 days when stored at room temperature. Formulation without sodium ascorbate injection or ascorbic acid tablet is stable for 14 days when refrigerated or 7 days when stored at room temperature.

Quality-Control Procedures — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

Labeling Requirements — Extemporaneously compounded preparation. For oral use only. Store at room temperature or refrigerate. Shake well before use.

Storage Conditions/Stability — Store at room temperature or refrigerate. Stable for 56 days when refrigerated and 14 days when stored at room temperature.

STABILITY STUDY DETAILS:

Study Container Type — Glass prescription bottle

Referenced Manufacturers — Captopril tablets (E.R. Squibb & Sons, LLC); distilled water (Magnetic Spring Bottled Water Co); sodium ascorbate injection (Eli Lilly & Co); ascorbic acid tablet (UDL Laboratories).

Stability-Indicating Study — Yes

REFERENCES

  • 1.

    Nahata MC, Morosco RS, Hipple TF. Stability of captopril in three liquid dosage forms. Am J Hosp Pharm. 1994;51(1):95–96.

  • 2.

    Nahata MC, Morosco RS, Hipple TF. Stability of captopril in liquid containing ascorbic acid or sodium ascorbate. Am J Hosp Pharm. 1994;51(13):1707–1708.

    • Search Google Scholar
    • Export Citation